# PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

> **NCT00536263** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 671 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** pegylated interferon alpha-2b
- **DRUG:** pegylated interferon alpha-2b
- **DRUG:** pegylated interferon alpha-2b

## Key facts

- **NCT ID:** NCT00536263
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 671 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536263, "PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00536263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*